Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Swollen lymph nodes may not be clinical manifestations of chronic myeloid leukemia: case report and revision of literature

Authors Liu Z, Li S, Bai O

Received 23 July 2017

Accepted for publication 19 August 2017

Published 5 September 2017 Volume 2017:13 Pages 1159—1162

DOI https://doi.org/10.2147/TCRM.S147056

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Hoa Le

Peer reviewer comments 2

Editor who approved publication: Professor Deyun Wang

Zhihe Liu,1 Siyun Li,2 Ou Bai1

1Department of Hematology, The First Hospital of Jilin University, Changchun, 2Department of Pediatrics, Women and Children’s hospital of Qingdao university, Qingdao, People’s Republic of China

Abstract: We present here the case of a 33-year-old Chinese female patient with synchronous double primary malignant tumors (chronic myeloid leukemia [CML] and classic Hodgkin lymphoma). This patient was admitted to our hospital because of bilateral cervical lymph node enlargement and recurrent fever for 2 weeks. The complete blood cell count revealed white blood cell counts of 18.2×109/L, hemoglobin of 9.6 g/dL, and platelet counts of 1,547×109/L. Chromosome karyotype analysis demonstrated that t(9;22)(q34;q11) was positive in all 20 cells examined. Reverse transcription polymerase chain reaction showed that the ratio of BCR/ABL1 to ABL was 45.3%. This patient was diagnosed with CML. After definite diagnosis, this patient regularly received imatinib therapy. Three months later, although complete blood count was normal, swollen lymph nodes further increased. Swollen lymph node biopsy was performed to evaluate the nature of these swollen lymph nodes, and results displayed that Hodgkin and Reed–Sternberg cells, CD30, CD15, and Epstein–Barr virus-encoded RNA was positive. In conclusion, this patient was diagnosed with synchronous double primary malignant tumors. This case report suggests that swollen lymph nodes may be due to lymphoma, rather than as a clinical manifestation of CML.

Keywords: imatinib, lymphoma, BCR/ABL1, fluorescence in situ hybridization
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author: